Technology | August 25, 2008

Medtronic Features Alternative Treatment System for Congenital Pulmonary Heart Valve Replacement

Medtronic's Melody Transcatheter Pulmonary Valve and Ensemble Transcatheter Delivery System treats patients requiring congenital pulmonary heart valve replacement.

The system is not FDA approved, but has gained Canadian approval and CE Mark approval. Currently, three U.S. hospitals are participating in clinical trials with the device, including Children’s Hospital Boston (Boston, MA), Morgan Stanley Children’s Hospital of NewYork - Presbyterian (New York, NY) and Miami Children’s Hospital (Miami, FL).

Oftentimes, this type of defect requires open-heart surgery early in life to implant a prosthetic or bioprosthetic valved-conduit to establish adequate blood flow from the heart to the lungs. However, the functional life span of these conduits is relatively limited, and as a result, most patients with this type of defect may require multiple open heart surgeries to place new valved conduits as they grow over their lifetime. To meet this clinical need, Medtronic will use this trial to evaluate the Melody valve and Ensemble delivery system as a catheter-based alternative treatment in order to restore effective pulmonary valve function and potentially prolong the functional life of the right ventricle to pulmonary artery conduits. This alternative treatment is designed to reduce the number of open-heart surgeries these patients must undergo.

Related Content

Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more
SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to
Radiation/Cisplatin Established as Standard of Care for HPV-related Head and Neck Cancer. #ASTRO #ASTRO18 #ASTRO2018
News | Radiation Oncology | October 30, 2018
October 30, 2018 — Combinations of radiation and chemotherapy drugs have been shown to cure human papilloma virus (HP
Overall survival of metastatic patients with SABR presented at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
News | Radiation Oncology | October 30, 2018
October 30, 2018 — In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggre